Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Checked against the public recordLast updated Aug 3, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Revolution Medicines, Inc.
- Interventions being studied
- Drug: Elironrasib; Drug: Daraxonrasib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * 18 years of age * Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy 1. Phase 1b Dose Escalation: solid tumors, previously treated 2. Phase 1b Dose Expansion and Phase 2: i. NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors. * ECOG performance status 0 or 1 * Adequate organ function Exclusion Criteria: * Primary central nervous system (CNS) tumors * Active brain metastases * Known impairment of GI function that would alter the absorption * Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of HopeDuarte, California
- UC IRVINE HealthOrange, California
- UC Davis Comprehensive Cancer CenterSacramento, California
- Stanford Cancer InstituteStanford, California
- University of Colorado Cancer CenterAurora, Colorado
- Florida Cancer SpecialistsSarasota, Florida
- Moffitt Cancer Center and Research InstituteTampa, Florida
- Community Health NetworkIndianapolis, Indiana
- Dana Farber Cancer InstituteBoston, Massachusetts
- Henry Ford CancerDetroit, Michigan
- START MidwestGrand Rapids, Michigan
- Columbia UniversityNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 3, 2026. Always confirm current availability with the study team.